hello world
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: Sernova Corp.
Today presented interim positive results from its ongoing Phase 1/2 clinical trial investigating islet allotransplantation into pre-vascularized Sernova Cell Pouch™ during an oral presentation at the 2023 IPITA, IXA, and CTRMS Joint Congress in San Diego, California. Sernova Corp. shares T.SVA are trading up $0.03 at $0.74.
